berberine and Diabetes Mellitus, Type 2 studies

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

Excerpt	Relevance	Reference
"Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease, NCT00633282 ."	9.41	Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. ( Chang, X; Gao, J; Ma, S; Wang, L; Wu, W; Xia, M; Yan, H, 2021)
"To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease."	9.15	[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. ( Kong, H; Meng, X; Shu, X; Xie, X; Zhou, X, 2011)
"One hundred sixteen patients with type 2 diabetes and dyslipidemia were randomly allocated to receive berberine (1."	9.13	Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. ( Hong, J; Huo, L; Li, X; Liu, W; Ning, G; Ren, G; Wang, M; Wu, P; Yang, J; Zhang, Y; Zhu, N; Zou, D, 2008)
"This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect."	8.91	Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015)
"Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota."	8.02	Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. ( Jiang, Y; Kong, Y; Liu, H; Ren, H; Shan, C; Wang, J; Wang, S; Wang, Y; Yang, J; Yang, Y; Zheng, M, 2021)
"The purpose of this study was to explore the anti-arrhythmic mechanisms of berberine in diabetic rats with myocardial infarction."	7.77	Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model. ( Fu, Y; Li, Q; Sun, YQ; Wang, LH; Yu, CH, 2011)
"This study will provide a high-quality synthesis of current evidence of BBR for T2DM with IR from several aspects including HOMA-IR, blood glucose levels, and adverse events."	6.61	Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. ( Li, H; Li, S; Liu, B; Wang, Y; Yan, A; Yan, Y, 2019)
" The bioavailability of berberine is extremely low, suggesting that it may play a role in lowering blood sugar and lipid by regulating intestinal flora."	6.55	[Berberine regulates type 2 diabetes mellitus related with insulin resistance]. ( He, JZ; Li, C; Xu, X; Zhou, XD, 2017)
"Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved."	5.51	Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. ( Dang, Y; Ji, G; Li, M; Li, Q; Yao, Z; Zhang, L; Zhou, W; Zuo, J, 2019)
"Treatment with berberine regulated BMP4 transcriptional pathways and brown adipose tissue transcriptional pathways and induced the gene mRNA expression of brown adipose tissue-specific genes in VWAT to develop browning gene phenotype of white adipose tissues, and then improved fat-induced insulin resistance."	5.43	[Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters]. ( Gao, ZN; Huang, L; Li, GS; Li, XY; Liu, XH; Liu, YL, 2016)
"Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease, NCT00633282 ."	5.41	Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. ( Chang, X; Gao, J; Ma, S; Wang, L; Wu, W; Xia, M; Yan, H, 2021)
"Berberine has been reported to have antidiabetic properties."	5.36	Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. ( Huang, L; Li, G; Liu, X; Liu, Y; Ma, C; Qin, C; Zhu, H, 2010)
"In animal models, treatment of type 2 diabetes mellitus rats with BBR lowered fasting blood glucose and fasting serum insulin, increased insulin sensitivity, and elevated InsR mRNA as well as PKC activity in the liver."	5.35	Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. ( Jiang, JD; Kong, WJ; Li, ZR; Pan, HN; Shan, N; Si, SY; Song, DQ; Wang, YM; Wei, J; Xue, R; Yang, P; You, XF; Zhang, H; Zhao, LX; Zhao, W; Zhou, ZX, 2009)
"To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease."	5.15	[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. ( Kong, H; Meng, X; Shu, X; Xie, X; Zhou, X, 2011)
"A comprehensive metabonomic method, in combination with fingerprint analysis and target analysis, was performed to reveal potential mechanisms of berberine action in the treatment of patients with type 2 diabetes and dyslipidemia."	5.14	Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. ( Chen, J; Gu, W; Gu, Y; Hong, J; Li, X; Lu, X; Ning, G; Shi, X; Xu, G; Zhang, Y, 2010)
"One hundred sixteen patients with type 2 diabetes and dyslipidemia were randomly allocated to receive berberine (1."	5.13	Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. ( Hong, J; Huo, L; Li, X; Liu, W; Ning, G; Ren, G; Wang, M; Wu, P; Yang, J; Zhang, Y; Zhu, N; Zou, D, 2008)
" Among these compounds, berberine, an isoquinoline alkaloid derived from plants of the generis Berberis, has been recognized as being capable of decreasing oxidative stress, LDL, triglycerides, and insulin resistance and of improving the mood."	4.91	Potential benefits of berberine in the management of perimenopausal syndrome. ( Caliceti, C; Cicero, AF; Rizzo, P, 2015)
"This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect."	4.91	Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015)
"Co-administration of metformin (250 mg/kg) with berberine (125 mg/kg) could not only further improve insulin sensitivity, but also demonstrate different alterations on gut microbial communities than that of their individual treatment in db/db mice."	4.12	Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice. ( Kong, APS; Li, D; Li, Z; Lyu, Y; Ming, X; Shaw, PC; Yuan, X; Zhang, C; Zhang, J; Zuo, Z, 2022)
"The aim of this study was to investigate the effects of berberine on polycystic ovary syndrome (PCOS) with insulin resistance (IR)."	4.02	Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites. ( Li, XL; Shen, HR; Xu, X; Ye, D, 2021)
"Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota."	4.02	Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. ( Jiang, Y; Kong, Y; Liu, H; Ren, H; Shan, C; Wang, J; Wang, S; Wang, Y; Yang, J; Yang, Y; Zheng, M, 2021)
"Diabetogenesis triggered by arsenic contributed to the mitochondrial ROS overproduction, impaired complex II activity, glucose homeostasis, glucose tolerance and insulin sensitivity."	3.91	SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification. ( Javadipour, M; Keshtzar, E; Khodayar, MJ; Rezaei, M, 2019)
"The purpose of this study was to explore the anti-arrhythmic mechanisms of berberine in diabetic rats with myocardial infarction."	3.77	Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model. ( Fu, Y; Li, Q; Sun, YQ; Wang, LH; Yu, CH, 2011)
"Berberine (BBR) is an isoquinoline alkaloid extracted from plants that possess a broad array of medicinal properties, including anti-diarrheal, anti-fibrotic, antidiabetic, anti-inflammatory, anti-obesity, antihyperlipidemic, antihypertensive, antiarrhythmic, antidepressant, and anxiolytic effects, and is frequently utilized as a traditional Chinese medicine."	2.82	Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. ( Albarrati, A; Albratty, M; Behl, T; Bungau, S; Meraya, AM; Najmi, A; Sharma, N; Singh, S; Zahoor, I, 2022)
"Berberine has been shown to regulate glucose and lipid metabolism in vitro and in vivo."	2.73	Efficacy of berberine in patients with type 2 diabetes mellitus. ( Xing, H; Ye, J; Yin, J, 2008)
"Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world."	2.72	Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. ( Li, L; Xie, J; Zhao, L, 2021)
"Berberine (BBR) is an isoquinoline alkaloid belonging to the structural class of protoberberines."	2.66	Nano-based delivery systems for berberine: A modern anti-cancer herbal medicine. ( Araj-Khodaei, M; Ezzati Nazhad Dolatabadi, J; Ghaffari, M; Hamblin, MR; Majidzadeh, H; Torbati, M, 2020)
" Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years."	2.61	Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. ( Chen, R; Huang, L; Liang, Y; Ni, J; Xu, X; Yin, M; Zhang, Y, 2019)
"This study will provide a high-quality synthesis of current evidence of BBR for T2DM with IR from several aspects including HOMA-IR, blood glucose levels, and adverse events."	2.61	Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. ( Li, H; Li, S; Liu, B; Wang, Y; Yan, A; Yan, Y, 2019)
" The bioavailability of berberine is extremely low, suggesting that it may play a role in lowering blood sugar and lipid by regulating intestinal flora."	2.55	[Berberine regulates type 2 diabetes mellitus related with insulin resistance]. ( He, JZ; Li, C; Xu, X; Zhou, XD, 2017)
"Berberine (BBR) is a type of alkaloids isolated from Coptidis Rhizoma and Phellodendri Chinensis Cortex and has been used to treat bacterial gastroenteritis, diarrhea and other digestive diseases for more than 1 000 years."	2.52	[Effect of berberine in treating type 2 diabetes mellitus and complications and its relevant mechanisms]. ( Chen, L; Li, Y; Zhang, Q, 2015)
"The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging."	2.52	Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. ( Chang, W; Chen, L; Hatch, GM, 2015)
"Berberine is an alkaloid that is highly concentrated in the roots, rhizomes, and stem bark of various plants."	2.48	Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. ( Cicero, AF; Tartagni, E, 2012)
"Berberine has significant antimicrobial activity against several microbes through inhibiting the assembly function of FtsZ and halting the bacteria cell division."	2.47	Modulating gut microbiota as an anti-diabetic mechanism of berberine. ( Han, J; Huang, W; Lin, H, 2011)
"Berberine (BBR) can ameliorate type 2 diabetes and insulin resistance in many ways."	1.91	Berberine Regulates GPX4 to Inhibit Ferroptosis of Islet β Cells. ( Bao, L; Han, J; Jin, Y; Qian, L; Wang, W; Wu, W, 2023)
" However, the chemical profiles, metabolic transformation and pharmacokinetic behavior of XEC in vivo were unclear."	1.91	Metabolic profiling integrated with pharmacokinetics to reveal the material basis of Xiaokeyinshui extract combination in the treatment of type 2 diabetes in rats. ( Chen, JC; Fang, JB; Fu, XN; He, JX; Hu, ZF; Huang, R; Li, Q; Luo, D; Peng, HM; Tong, QL; Wan, LS; Wu, JL; Xia, RF; Xiang, ZN; Zhang, YL, 2023)
"Berberine chloride is a dual topoisomerase I and II inhibitor, that exhibited potent antitumor activities against several malignancies."	1.91	Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production. ( Abdalla, M; Ferdous, MR; Song, Y; Xiaoling, L; Yang, M, 2023)
"Berberine (BBR) is an isoquinoline alkaloid isolated from Coptis chinensis and possesses valuable pharmacological activities, including anti-inflammatory, anti-tumor, and alleviating several complications of type 2 diabetes mellitus (T2DM)."	1.72	Alleviation of Diabetic Tendon Injury via Activation of Tendon Fibroblasts Autophagy under Berberine Treatment. ( Li, Q; Liu, SH; Song, FC; Yuan, JQ; Zhang, L; Zhao, C; Zhu, MD, 2022)
"Among adolescents, the incidence of type 2 diabetes mellitus (T2DM) has recently increased."	1.62	Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: A case report. ( Chan, Y; Hou, S; Lao, L; Shao, B; Shao, C, 2021)
"Rat models of type 2 diabetes mellitus (T2DM) were established and were treated with berberine."	1.62	Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats. ( Chen, M; Gu, L; Si, Y; Wu, Z; Yin, W; Zhang, T; Zhao, M, 2021)
"Berberine is effective for type 2 diabetes mellitus (T2DM), but has limited use in clinic."	1.62	Berberine combined with stachyose improves glycometabolism and gut microbiota through regulating colonic microRNA and gene expression in diabetic rats. ( Cao, H; Fu, Y; Gao, X; Huan, Y; Ji, W; Lei, L; Li, C; Li, P; Liu, M; Liu, Q; Liu, S; Shen, Z; Sun, S, 2021)
"Berberine (BBR) has therapeutic effect on diabetic nephropathy (DN), but its molecular mechanism is not completely clear."	1.62	Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells. ( Gan, L; Hu, Y; Liu, L; Xiang, P; Xing, Y; Xu, J; Ye, S; Zhu, J, 2021)
" However, its oral bioavailability is poor."	1.56	Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids. ( Chen, H; Wang, D; Wang, W; Yan, L; Yao, Y, 2020)
"Berberine (BBR) has been proved to possess the properties of improving metabolic disorders in patients with obesity or type 2 diabetes mellitus."	1.56	Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. ( Jin, L; Meng, X; Ning, G; Wang, W; Yang, J; Yao, S; Yuan, Y; Zhang, H; Zhang, Y; Zhang, Z, 2020)
" However, the low anti-diabetic activity and poor bioavailability of berberine (below 5%) by oral administration significantly limit its practical applications."	1.56	Synthesis of disaccharide modified berberine derivatives and their anti-diabetic investigation in zebrafish using a fluorescence-based technology. ( Jin, M; Kong, H; Li, X; Lin, H; Liu, K; Stoika, R; Wang, L, 2020)
" However, the poor bioavailability of berberine limits its clinical applications."	1.56	Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy. ( Chen, L; Guan, F; Wang, X; Xiao, D; Zhang, J; Zhang, M; Zhang, Y, 2020)
"Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved."	1.51	Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. ( Dang, Y; Ji, G; Li, M; Li, Q; Yao, Z; Zhang, L; Zhou, W; Zuo, J, 2019)
"Berberine was administered p."	1.48	Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3β Pathway. ( Chen, J; Chen, Q; Feng, Z; Hang, W; He, B; Wang, S; Wang, X; Wu, N; Xia, L; Zhang, Q; Zhou, X, 2018)
"Pioglitazone treatment significantly increased urinary calcium, serum TRAP, mRNA expression of RANKL, PPAR-γ as well as significantly decreased Runx2, OPG, osteocalcin and AMPK levels in diabetic rats."	1.46	Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. ( Adil, M; Kandhare, AD; Mansoori, MN; Sharma, M; Singh, D, 2017)
"Treatment with berberine regulated BMP4 transcriptional pathways and brown adipose tissue transcriptional pathways and induced the gene mRNA expression of brown adipose tissue-specific genes in VWAT to develop browning gene phenotype of white adipose tissues, and then improved fat-induced insulin resistance."	1.43	[Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters]. ( Gao, ZN; Huang, L; Li, GS; Li, XY; Liu, XH; Liu, YL, 2016)
"Berberine (BBR) has been shown to exhibit protective effects against diabetes and dyslipidemia."	1.43	Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway. ( Chen, L; Hatch, GM; Lan, X; Wei, S; Yan, X; Yao, F; Yu, Y; Zhang, M, 2016)
"Berberine (BBR) has been reported to have beneficial effects on diabetic nephropathy, but its action mechanism is still unclear."	1.42	Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. ( Dong, X; Huang, XR; Lan, HY; Li, P; Pan, XP; Sun, SF; Wang, H; Wen, YM; Yan, MH; Zhang, HJ; Zhang, L; Zhang, WK; Zhao, TT, 2015)
"Berberine treatment of palmitate-incubated H9c2 cells reduced hypertrophy, increased α-MHC expression and decreased β-MHC expression."	1.42	Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. ( Chang, W; Chen, L; Hatch, GM; Meng, Z; Yao, F; Yu, Y; Zhang, M, 2015)
"This article focused on a comparative analysis on the pharmacokinetic and pharmacodynamic characteristics of berberine (BER) and jateorhizine(JAT) in Coptidis Rhizoma powder (HL-P) and their monomeric compounds (BER + JAT, BJ) in type 2 diabetic (T2D) rats to explore the beneficial."	1.42	[Pharmacokinetic and pharmacodynamic characteristics of berberine and jateorhizine in Coptidis Rhizoma powder and their monomeric compounds in type 2 diabetic rats]. ( Huang, R; Jiang, SJ; Li, JB; Lu, FE; Wei, SC; Xu, LJ; Xu, XH; Zou, X, 2015)
"Low oral bioavailability of berberine due to poor solubility and membrane permeability limits its clinical use for treatment of diabetes."	1.40	Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. ( Hatch, GM; Jingkai, G; Li, C; Ming, Z; Shengnan, W; Xiaojia, B; Zhaojie, M, 2014)
"Berberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into the blood stream from the gut."	1.40	Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. ( Li, M; Li, W; Ping, F; Wang, Z; Xiao, X; Yu, M; Zhang, H; Zhang, Q; Zheng, J, 2014)
"Berberine (100 mg/kg) was administered by lavage to diabetic rats for 2 weeks and saline was given to controls."	1.39	Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. ( Chang, BC; Chen, LM; Kong, Y; Ren, HZ; Shan, CY; Wang, XY; Wang, Y; Xu, YG; Yang, JH; Zheng, MY, 2013)
"Berberine has been widely used as an alternative medicine and proved to be effective for treatment of DM and dyslipidemia."	1.38	Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine. ( Chatuphonprasert, W; Jarukamjorn, K; Lao-ong, T; Nemoto, N, 2012)
"Berberine (BBR) is a compound originally identified in a Chinese herbal medicine Huanglian (Coptis chinensis French)."	1.37	Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. ( Liang, H; Shen, Y; Tang, K; Weng, J; Xia, X; Yan, J; Yang, D; Ye, J; Yin, J; Zhang, Y, 2011)
"Berberine has been reported to have antidiabetic properties."	1.36	Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. ( Huang, L; Li, G; Liu, X; Liu, Y; Ma, C; Qin, C; Zhu, H, 2010)
"Berberine has hypoglycemic and hypolipidemic effects on diabetic rats."	1.36	Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. ( Zhou, J; Zhou, S, 2010)
"In animal models, treatment of type 2 diabetes mellitus rats with BBR lowered fasting blood glucose and fasting serum insulin, increased insulin sensitivity, and elevated InsR mRNA as well as PKC activity in the liver."	1.35	Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. ( Jiang, JD; Kong, WJ; Li, ZR; Pan, HN; Shan, N; Si, SY; Song, DQ; Wang, YM; Wei, J; Xue, R; Yang, P; You, XF; Zhang, H; Zhao, LX; Zhao, W; Zhou, ZX, 2009)
" In conclusion, berberine restores diabetic endothelial dysfunction through enhanced NO bioavailability by up-regulating eNOS expression and down-regulating expression of NADPH oxidase."	1.35	Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. ( Chen, L; Li, J; Liu, Y; Lv, X; Song, Y; Wang, C; Zhang, M, 2009)

Research

Studies (99)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.01)	18.7374
1990's	1 (1.01)	18.2507
2000's	8 (8.08)	29.6817
2010's	53 (53.54)	24.3611
2020's	36 (36.36)	2.80

Authors	Studies
Zhang, S	1
Wang, X	7
Yin, W	2
Liu, Z	2
Zhou, M	1
Xiao, D	2
Liu, Y	3
Peng, D	1
Li, C	4
Cao, H	1
Huan, Y	1
Ji, W	1
Liu, S	1
Sun, S	1
Liu, Q	1
Lei, L	1
Liu, M	1
Gao, X	1
Fu, Y	2
Li, P	3
Shen, Z	1
Shen, HR	1
Xu, X	4
Ye, D	1
Li, XL	1
Xu, J	2
Liu, L	2
Gan, L	1
Hu, Y	1
Xiang, P	1
Xing, Y	1
Zhu, J	1
Ye, S	1
Harrison, SA	1
Gunn, N	1
Neff, GW	1
Kohli, A	1
Flyer, A	1
Goldkind, L	1
Di Bisceglie, AM	1
Guo, J	1
Chen, H	2
Zhang, X	4
Lou, W	1
Zhang, P	2
Qiu, Y	2
Zhang, C	2
Wang, Y	6
Liu, WJ	1
Zhang, L	4
Han, L	3
Ma, J	2
Wu, T	1
Wei, Y	1
Zhao, L	5
Tong, X	4
Zhu, MD	1
Li, Q	7
Yuan, JQ	1
Song, FC	1
Liu, SH	1
Zhao, C	1
Xia, QS	1
Wu, F	1
Wu, WB	1
Dong, H	4
Huang, ZY	1
Xu, L	1
Lu, FE	2
Gong, J	1
Zhang, JJ	1
Zhou, R	1
Deng, LJ	1
Cao, GZ	1
Zhang, Y	8
Xu, H	1
Hou, JY	1
Ju, S	1
Yang, HJ	1
Lyu, Y	1
Li, D	1
Yuan, X	1
Li, Z	1
Zhang, J	2
Ming, X	1
Shaw, PC	1
Kong, APS	1
Zuo, Z	1
Ferdous, MR	1
Abdalla, M	1
Yang, M	1
Xiaoling, L	1
Song, Y	2
Behl, T	2
Singh, S	2
Sharma, N	2
Zahoor, I	1
Albarrati, A	1
Albratty, M	1
Meraya, AM	1
Najmi, A	1
Bungau, S	2
Zheng, T	1
Huo, Y	1
Du, W	1
Bi, XJ	1
Lv, YQ	1
Yang, XH	1
Ge, Y	1
Han, H	1
Feng, JS	1
Zhang, M	9
Chen, L	12
Xu, MZ	1
Guan, FY	1
Wang, H	3
Zhang, H	5
Gao, Z	5
Zhang, Q	4
Gu, C	1
Bao, L	1
Jin, Y	1
Han, J	3
Wang, W	4
Qian, L	1
Wu, W	2
Li, H	4
Luo, D	4
Wei, R	3
Sun, M	3
Deng, H	3
Bian, W	3
Wei, H	3
Huang, Y	3
He, Q	3
Guo, Y	3
Gong, M	3
Xia, Q	3
Lu, F	3
Wang, D	4
Tong, QL	1
Xiang, ZN	1
Zhang, YL	1
He, JX	1
Hu, ZF	1
Xia, RF	1
Wu, JL	1
Fu, XN	1
Peng, HM	1
Huang, R	2
Wan, LS	1
Chen, JC	1
Fang, JB	1
Bellavite, P	1
Fazio, S	1
Affuso, F	1
Chen, Y	1
Zhao, S	1
Sun, L	1
Yin, Z	1
Li, X	5
Iwakiri, Y	1
Duan, Y	1
Yan, A	1
Li, S	1
Liu, B	1
Yan, Y	1
Zhang, W	2
Xu, JH	1
Yu, T	1
Chen, QK	1
Guan, F	2
Wang, L	2
Kong, H	2
Jin, M	1
Stoika, R	1
Lin, H	2
Liu, K	1
Majidzadeh, H	1
Araj-Khodaei, M	1
Ghaffari, M	1
Torbati, M	1
Ezzati Nazhad Dolatabadi, J	1
Hamblin, MR	1
Yao, S	1
Yuan, Y	1
Meng, X	2
Jin, L	1
Yang, J	5
Ning, G	4
Zhang, Z	1
Wu, Z	2
Gu, L	1
Si, Y	1
Zhao, M	1
Zhang, T	1
Chen, M	1
Yao, Y	1
Yan, L	1
Gu, Y	2
Ren, H	2
Wang, S	3
Zhong, H	1
Zhao, X	2
Gu, X	1
Xue, Y	1
Huang, S	1
Chen, G	1
Qu, S	1
Liang, J	1
Qin, L	2
Huang, Q	1
Peng, Y	1
Kong, P	1
Hou, G	1
Gao, M	1
Shi, Z	1
Zou, Y	1
Yang, H	1
Wang, J	3
Xu, G	2
Lai, S	1
Li, J	3
Shao, B	1
Hou, S	1
Chan, Y	1
Shao, C	1
Lao, L	1
Yang, F	2
Yang, Y	3
Zhao, N	1
Ma, Y	1
Shu, L	1
Hu, X	1
Lyu, N	1
Pan, Y	1
Zhu, B	1
Yan, H	1
Chang, X	1
Xia, M	1
Ma, S	1
Gao, J	1
Fan, CF	1
Guo, YS	1
Wang, JH	1
Zhang, HL	1
Xie, J	1
Li, L	1
Di, S	1
An, X	1
Kong, R	1
Ding, Q	1
Wu, H	1
Liu, H	2
Zheng, M	1
Kong, Y	2
Jiang, Y	1
Shan, C	1
Gupta, A	1
Sehgal, A	1
Sharma, S	1
Diaconu, CC	1
Rahdar, A	1
Hafeez, A	1
Bhatia, S	1
Al-Harrasi, A	1
Sahebkar, A	1
Watts, GF	1
Adil, M	1
Mansoori, MN	1
Singh, D	1
Kandhare, AD	1
Sharma, M	1
He, JZ	1
Zhou, XD	1
Li, GS	2
Liu, XH	2
Li, XY	1
Gao, ZN	1
Huang, L	4
Liu, YL	2
Jiang, YY	1
Cui, HM	1
Wang, JL	1
Dang, MM	1
Zhang, QY	1
Kou, JT	1
Tong, XL	1
Chang, W	4
Hatch, GM	6
Wu, X	2
Ming, J	1
Xu, S	1
Liu, C	1
Liu, X	2
Jia, A	1
Ji, Q	1
He, B	1
Hang, W	1
Wu, N	1
Xia, L	1
Zhou, X	3
Feng, Z	1
Chen, Q	1
Chen, J	2
Rezaei, M	1
Keshtzar, E	1
Khodayar, MJ	1
Javadipour, M	1
Liang, Y	1
Yin, M	1
Chen, R	1
Ni, J	1
Jia, D	1
Li, ZW	1
Gao, Y	1
Feng, Y	2
Ma, M	1
Li, W	3
Li, M	2
Dang, Y	1
Zhou, W	1
Zuo, J	1
Yao, Z	1
Ji, G	1
Shan, CY	1
Yang, JH	1
Wang, XY	1
Zheng, MY	1
Xu, YG	1
Ren, HZ	1
Chang, BC	1
Chen, LM	1
Yao, J	1
Kong, W	1
Jiang, J	1
Zhaojie, M	1
Ming, Z	1
Shengnan, W	1
Xiaojia, B	1
Jingkai, G	1
Li, R	1
Wu, J	1
He, Y	1
Hai, L	1
Wu, Y	1
Xiao, X	1
Yu, M	1
Ping, F	1
Wang, Z	1
Zheng, J	1
Deng, XW	1
Xie, N	1
Lan, J	1
Zhao, Y	1
Dong, F	1
Yan, Z	1
Zheng, W	1
Fan, J	1
Sun, G	1
Caliceti, C	1
Rizzo, P	1
Cicero, AF	2
Sun, SF	1
Zhao, TT	1
Zhang, HJ	1
Huang, XR	1
Zhang, WK	1
Yan, MH	1
Dong, X	1
Wen, YM	1
Pan, XP	1
Lan, HY	1
Li, Y	2
Luthra, A	2
Misra, A	2
Mudur, G	1
Meng, Z	1
Yu, Y	3
Yao, F	3
Wang, Q	1
Jain, M	1
Jani, RH	1
Pareek, A	1
Chandurkar, N	1
Li, K	1
Dong, Y	1
Chen, YT	1
Yang, YX	1
Zhou, XJ	1
Dai, SJ	1
Tong, JF	1
Shou, D	1
Wei, S	1
Lan, X	1
Yan, X	1
Wei, SC	1
Xu, LJ	1
Zou, X	1
Li, JB	1
Jiang, SJ	1
Xu, XH	1
Kong, WJ	2
Song, DQ	2
Xue, R	2
Zhao, W	3
Wei, J	2
Wang, YM	2
Shan, N	1
Zhou, ZX	2
Yang, P	1
You, XF	1
Li, ZR	1
Si, SY	1
Zhao, LX	1
Pan, HN	2
Jiang, JD	2
Xu, YC	1
Guo, FJ	1
Meng, Y	1
Li, ML	1
Lv, XY	1
Xu, ZG	1
Wang, C	1
Lv, X	1
Wu, JD	1
Wang, ZZ	1
Wang, SK	1
Shi, X	1
Hong, J	2
Gu, W	1
Lu, X	1
Campbell, T	1
Perry, B	1
Beaurepaire, C	1
Wang, LH	1
Yu, CH	1
Sun, YQ	1
Li, G	1
Zhu, H	2
Ma, C	1
Qin, C	2
Zhou, J	1
Zhou, S	1
Xia, X	1
Yan, J	1
Shen, Y	1
Tang, K	1
Yin, J	3
Yang, D	1
Liang, H	1
Ye, J	3
Weng, J	1
Ma, CM	1
Huang, W	1
Tang, YH	1
Sun, ZL	1
Fan, MS	1
Li, ZX	1
Huang, CG	1
Xie, X	1
Shu, X	1
Tartagni, E	1
Lao-ong, T	1
Chatuphonprasert, W	1
Nemoto, N	1
Jarukamjorn, K	1
Feng, XT	1
Leng, J	1
Xie, Z	1
Li, SL	1
Tang, QL	1
Bharti, SK	1
Krishnan, S	1
Kumar, A	1
Rajak, KK	1
Murari, K	1
Bharti, BK	1
Gupta, AK	1
Liu, D	1
Zhou, JY	1
Zhou, SW	1
Zou, D	1
Liu, W	1
Zhu, N	1
Huo, L	1
Wang, M	1
Wu, P	1
Ren, G	1
Xing, H	1
Ni, YX	2
Fan, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM[NCT03656744]	Phase 2	101 participants (Actual)	Interventional	2018-11-26	Completed
Assess the Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals With Obesity and Non-alcoholic Fatty Liver Disease[NCT05647915]	Phase 4	326 participants (Anticipated)	Interventional	2022-12-15	Not yet recruiting
Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: A Randomized Controlled Trial[NCT04698330]	Phase 4	240 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
Probiotics and BeRberine on the Efficacy and Change of Gut MicrObiota in paTients With Newly Diagnosed Type 2 diabEtes（PREMOTE Study）[NCT02861261]	Phase 3	400 participants (Anticipated)	Interventional	2016-08-18	Active, not recruiting
Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282]	Phase 2	184 participants (Actual)	Interventional	2008-03-31	Completed
Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.[NCT03330184]		300 participants (Actual)	Interventional	2015-10-31	Completed
Effect of Berberine on Cardiovascular Disease Risk Factors: a Mechanistic Randomized Controlled Trial[NCT03770325]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2019-04-01	Completed
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934]	Phase 4	64 participants (Anticipated)	Interventional	2018-09-26	Recruiting
A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188]	Phase 2/Phase 3	113 participants (Actual)	Interventional	2018-04-25	Completed
The Effect of Berberine on the Secretion of Incretin in Normal Man[NCT05947370]	Early Phase 1	16 participants (Actual)	Interventional	2022-10-12	Completed
Efficacy and Safety of Berberine on Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome: a Randomized, Controlled Trial[NCT05105321]	Phase 4	5,200 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-16	Recruiting
The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878]		20 participants (Anticipated)	Interventional	2023-07-10	Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The primary endpoint was the absolute change in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study Week 18

Change in ALT

Intervention	Change in percentage of liver fat (Mean)
500mg HTD1801, Bid	-2.918
1000mg HTD1801, Bid	-4.829
Placebo, Bid	-1.962

Absolute change in alanine aminotransferase (ALT) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in AST

Intervention	U/L (Mean)
500mg HTD1801, Bid	-4
1000mg HTD1801, Bid	-19
Placebo, Bid	-3

Absolute change in aspartate aminotransferase (AST) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in ELF Score

Intervention	U/L (Mean)
500mg HTD1801, Bid	0
1000mg HTD1801, Bid	-13
Placebo, Bid	-3

Change in the enhanced liver fibrosis (ELF) score. The ELF score is calculated using a published algorithm combining the values of a set of extracellular matrix markers, including TIMP-1, PIIINP, and HA. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score < 9.8 : Low risk of progression, ELF score 9.8 to < 11.3 : Moderate risk of progression and ELF score > = 11.3 : High risk of progression. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Fasting Glucose

Intervention	score on a scale (Mean)
500mg HTD1801, Bid	0.05
1000mg HTD1801, Bid	-0.10
Placebo, Bid	-0.05

Change in fasting glucose from Baseline to Week 18 . (NCT03656744)
Timeframe: Baseline through study Week 18

Change in FGF19

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	120
1000mg HTD1801, Bid	129
Placebo, Bid	131

Change in fibroblast growth factor 19 (FGF19) from Baseline to Week 18 (NCT03656744)
Timeframe: Baseline through study week 18

Change in HA

Intervention	μmol/L (Mean)
500mg HTD1801, Bid	-11
1000mg HTD1801, Bid	-9
Placebo, Bid	-40

Change in hyaluronic acid (HA) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in HDL-c

Intervention	µg/L (Mean)
500mg HTD1801, Bid	-0.64
1000mg HTD1801, Bid	-5.25
Placebo, Bid	-3.83

Change in high-density lipoprotein cholesterol (HDL-c) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in HOMA-IR

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	1
1000mg HTD1801, Bid	0
Placebo, Bid	0

Change in homeostasis model assessment-estimated insulin resistance (HOMA-IR) from Baseline to Week 18. The higher the HOMA-IR score, the more insulin resistant a person is. Values of <1 are considered optimal while values >2.9 indicate significant insulin resistance. (NCT03656744)
Timeframe: Baseline through study week 18

Change in LDL-c

Intervention	score on a scale (Mean)
500mg HTD1801, Bid	-3.38
1000mg HTD1801, Bid	-4.21
Placebo, Bid	-6.66

Change in low-density lipoprotein cholesterol (LDL-c) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline visit through study week 18

Change in PIIINP

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	5
1000mg HTD1801, Bid	-16
Placebo, Bid	0

Change in N-terminal pro-peptide of type III collagen (PIIINP) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Pro-Peptide of Type III Collagen (Pro-C3)

Intervention	µg/L (Mean)
500mg HTD1801, Bid	0.68
1000mg HTD1801, Bid	0.03
Placebo, Bid	-0.31

Change in Pro-C3 from Baseline to Week 18 for subjects with elevated Pro-C3 at Baseline. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Serum Triglycerides

Intervention	ng/mL (Mean)
500mg HTD1801, Bid	0.5
1000mg HTD1801, Bid	-2.3
Placebo, Bid	-0.8

Change in serum triglycerides from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in TIMP-1

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	-41
1000mg HTD1801, Bid	-24
Placebo, Bid	18

Change in tissue inhibitor of metalloproteinases 1 (TIMP-1) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Total Bile Acids

Intervention	µg/L (Mean)
500mg HTD1801, Bid	1.8
1000mg HTD1801, Bid	-8.9
Placebo, Bid	-6.0

Changes in total bile acids from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Changes in Hemoglobin A1c

Intervention	μmol/L (Mean)
500mg HTD1801, Bid	1307
1000mg HTD1801, Bid	1625
Placebo, Bid	-581

Changes in HbA1c from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Number of Participants Reporting an Adverse Events From Baseline Through Week 18

Intervention	Percentage (Mean)
500mg HTD1801, Bid	-0.3
1000mg HTD1801, Bid	-0.6
Placebo, Bid	0.1

AEs were mapped to MedDRA version 20.1 preferred term (PT) and system organ class (SOC). If the subject experienced multiple events that mapped to a single preferred term, the greatest severity grade according to CTCAE Version 4.0, and strongest investigator assessment of relation to study medication was assigned to the preferred term. If an event had a missing severity or relationship, it was classified as having the highest severity and/or strongest relationship to study medication. The occurrence of TEAEs was summarized by treatment group by SOC, PT, and severity. Separate summaries of treatment-emergent serious adverse events (SAEs), TEAEs related to study drug, severe or life threatening TEAEs, and TEAEs leading to the discontinuation of study treatment were generated. Additionally, the occurrence of liver-specific AEs was summarized by treatment group. All reported adverse events were listed for individual subjects showing verbatim term, PT and SOC. (NCT03656744)
Timeframe: Adverse events were collected from the time the subject signed the informed consent form through the date of the last visit for a specific subject, that is, approximately 24 weeks in total for a completed subject.

Number of Subjects Who Achieved ≥5% Absolute Reduction in Liver Fat Content (LFC) as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	21
1000mg HTD1801, Bid	26
Placebo, Bid	20

Number of subjects who achieved ≥5% absolute reduction in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study Week 18

Number of Subjects Who Normalized LFC to <5% as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	10
1000mg HTD1801, Bid	12
Placebo, Bid	8

Number of subjects who normalized liver fat content (LFC) to <5% as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) at Week 18. (NCT03656744)
Timeframe: Baseline through study Week 18

Proportion of Subjects Who Achieved ≥ 30% Relative Reduction in LFC as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	1
1000mg HTD1801, Bid	0
Placebo, Bid	0

Proportion of subjects who achieved ≥ 30% relative reduction in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Proportion of Subjects With Elevated ALT at Baseline Who Normalized ALT at Week 18

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	6
1000mg HTD1801, Bid	10
Placebo, Bid	7

Proportion of subjects with elevated alanine aminotransferase (ALT) at Baseline who normalized ALT at Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Relative Change in LFC as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	3
1000mg HTD1801, Bid	9
Placebo, Bid	5

Relative change in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Article	Year
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Berberine; Diabetes Mellitus, Type 2; Humans; Randomized Controlled Trials as Topic	2021
Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. Molecules (Basel, Switzerland), 2022, Jun-09, Volume: 27, Issue:12 Topics: Alkaloids; Anti-Inflammatory Agents; Berberine; Diabetes Mellitus, Type 2; Female; Humans; Nanotechn	2022
The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Frontiers in cellular and infection microbiology, 2022, Volume: 12 Topics: Bacteria; Berberine; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Non-alcoholic F	2022
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus. Frontiers in endocrinology, 2022, Volume: 13 Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re	2022
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus. Frontiers in endocrinology, 2022, Volume: 13 Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re	2022
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus. Frontiers in endocrinology, 2022, Volume: 13 Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re	2022
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus. Frontiers in endocrinology, 2022, Volume: 13 Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re	2022
A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention. Molecules (Basel, Switzerland), 2023, Jun-01, Volume: 28, Issue:11 Topics: Animals; Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance;	2023
Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. Medicine, 2019, Volume: 98, Issue:35 Topics: Berberine; Blood Glucose; China; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Randomized C	2019
Nano-based delivery systems for berberine: A modern anti-cancer herbal medicine. Colloids and surfaces. B, Biointerfaces, 2020, Volume: 194 Topics: Antineoplastic Agents; Apoptosis; Berberine; Diabetes Mellitus, Type 2; Herbal Medicine; Humans	2020
Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. Mini reviews in medicinal chemistry, 2021, Volume: 21, Issue:19 Topics: Berberine; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Liver; Non-alcoholic Fatty Liver D	2021
A spotlight on underlying the mechanism of AMPK in diabetes complications. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2021, Volume: 70, Issue:9 Topics: AMP-Activated Protein Kinases; Animals; Berberine; Diabetes Complications; Diabetes Mellitus, Type 2	2021
Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications? Current opinion in lipidology, 2017, Volume: 28, Issue:3 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Lipid Metabolism; Lipids; Non-	2017
[Berberine regulates type 2 diabetes mellitus related with insulin resistance]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2017, Volume: 42, Issue:12 Topics: Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Humans; Hypoglycemic Agents; Insulin Re	2017
New Insights into the Mechanisms of Chinese Herbal Products on Diabetes: A Focus on the "Bacteria-Mucosal Immunity-Inflammation-Diabetes" Axis. Journal of immunology research, 2017, Volume: 2017 Topics: Animals; Berberine; Curcumin; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Gastrointestinal Mic	2017
Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocrine journal, 2019, Jan-28, Volume: 66, Issue:1 Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glycated He	2019
Learning from berberine: Treating chronic diseases through multiple targets. Science China. Life sciences, 2015, Volume: 58, Issue:9 Topics: Berberine; China; Chronic Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hyperlipidemia	2015
[Progress of berberine for treatment of type 2 diabetes]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2014, Volume: 39, Issue:8 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin; Lipid	2014
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 2015, Feb-23, Volume: 161 Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension	2015
Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochemistry and cell biology = Biochimie et biologie cellulaire, 2015, Volume: 93, Issue:5 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents	2015
Potential benefits of berberine in the management of perimenopausal syndrome. Oxidative medicine and cellular longevity, 2015, Volume: 2015 Topics: Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; L	2015
[Effect of berberine in treating type 2 diabetes mellitus and complications and its relevant mechanisms]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2015, Volume: 40, Issue:9 Topics: Animals; Berberine; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Drugs, Chinese	2015
Modulating gut microbiota as an anti-diabetic mechanism of berberine. Medical science monitor : international medical journal of experimental and clinical research, 2011, Volume: 17, Issue:7 Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Tract; Gene Expressio	2011
Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. Hospital practice (1995), 2012, Volume: 40, Issue:2 Topics: Animals; Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents;	2012
GPR40: a therapeutic target for mediating insulin secretion (review). International journal of molecular medicine, 2012, Volume: 30, Issue:6 Topics: Animals; Benzofurans; Berberine; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Fatt	2012

Article	Year
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications, 2020, 10-06, Volume: 11, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Female; Gastrointestinal Microbiome; Glycated Hemoglobin; Huma	2020
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications, 2020, 10-06, Volume: 11, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Female; Gastrointestinal Microbiome; Glycated Hemoglobin; Huma	2020
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications, 2020, 10-06, Volume: 11, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Female; Gastrointestinal Microbiome; Glycated Hemoglobin; Huma	2020
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications, 2020, 10-06, Volume: 11, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Female; Gastrointestinal Microbiome; Glycated Hemoglobin; Huma	2020
Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biology of sex differences, 2021, 01-04, Volume: 12, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Male; Non-alcoholic Fatty Liver Disea	2021
Effectiveness and safety of bifidobacteria and berberine in people with hyperglycemia: study protocol for a randomized controlled trial. Trials, 2018, Jan-26, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Berberine; Bifidobacterium; Biomarkers; Blood Glucose; Child; China; Combin	2018
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism: clinical and experimental, 2010, Volume: 59, Issue:2 Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Human	2010
Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta, 2010, May-15, Volume: 81, Issue:3 Topics: Aged; Berberine; Chromatography, Liquid; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemi	2010
[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2011, Volume: 36, Issue:21 Topics: Adult; Alanine Transaminase; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Fatty Live	2011
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:7 Topics: Adult; Aged; Berberine; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidem	2008
Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:5 Topics: Adult; Aged; Berberine; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema	2008
[Clinical study on jiang tang san in treating non-insulin dependent diabetes mellitus patients]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1994, Volume: 14, Issue:11 Topics: Adult; Aged; Berberine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drugs, Chinese Her	1994

Article	Year
Synthesis and hypoglycemic activity of 9-O-(lipophilic group substituted) berberine derivatives. Bioorganic & medicinal chemistry letters, 2016, 10-01, Volume: 26, Issue:19 Topics: Berberine; Diabetes Mellitus, Type 2; Hep G2 Cells; Humans; Hypoglycemic Agents; Spectrum Analysis	2016
Berberine combined with stachyose improves glycometabolism and gut microbiota through regulating colonic microRNA and gene expression in diabetic rats. Life sciences, 2021, Nov-01, Volume: 284 Topics: Animals; Berberine; Colon; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastrointesti	2021
Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites. Gynecologic and obstetric investigation, 2021, Volume: 86, Issue:4 Topics: Animals; Berberine; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Female; Gastrointestinal Micr	2021
Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells. Frontiers in endocrinology, 2021, Volume: 12 Topics: Animals; Apoptosis; Berberine; CCAAT-Enhancer-Binding Protein-beta; Diabetes Mellitus, Experimental;	2021
Exploring the synergistic and complementary effects of berberine and paeoniflorin in the treatment of type 2 diabetes mellitus by network pharmacology. European journal of pharmacology, 2022, Mar-15, Volume: 919 Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drugs, Chinese	2022
Alleviation of Diabetic Tendon Injury via Activation of Tendon Fibroblasts Autophagy under Berberine Treatment. Journal of visualized experiments : JoVE, 2022, 03-11, Issue:181 Topics: Animals; Apoptosis; Autophagy; Berberine; Diabetes Mellitus, Type 2; Fibroblasts; Rats; Tendon Injur	2022
Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2α. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 150 Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Berberine; Ceramides; Diabetes Mellitus, Type	2022
Huangbai liniment and berberine promoted wound healing in high-fat diet/Streptozotocin-induced diabetic rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 150 Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug	2022
Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 101 Topics: Animals; Berberine; Chromatography, Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type	2022
Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production. Journal of biomolecular structure & dynamics, 2023, Volume: 41, Issue:5 Topics: Adenosine Triphosphate; Adipocytes, Brown; Adipose Tissue, Brown; Berberine; Chlorides; Diabetes Mel	2023
Exploration of Isoquinoline Alkaloids as Potential Inhibitors against Human Islet Amyloid Polypeptide. ACS chemical neuroscience, 2022, 07-20, Volume: 13, Issue:14 Topics: Amyloid; Berberine; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; Isoquinolines; Pro	2022
A New Berberine Preparation Protects Pancreatic Islet Cells from Apoptosis Mediated by Inhibition of Phospholipase A Bulletin of experimental biology and medicine, 2022, Volume: 173, Issue:3 Topics: Animals; Apoptosis; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin-S	2022
Berberine Regulates GPX4 to Inhibit Ferroptosis of Islet β Cells. Planta medica, 2023, Volume: 89, Issue:3 Topics: Berberine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ferroptosis; Reactive Oxygen Specie	2023
Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular Docking. BioMed research international, 2022, Volume: 2022 Topics: Antineoplastic Agents; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Eupatorium; Inte	2022
Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular Docking. BioMed research international, 2022, Volume: 2022 Topics: Antineoplastic Agents; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Eupatorium; Inte	2022
Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular Docking. BioMed research international, 2022, Volume: 2022 Topics: Antineoplastic Agents; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Eupatorium; Inte	2022
Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular Docking. BioMed research international, 2022, Volume: 2022 Topics: Antineoplastic Agents; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Eupatorium; Inte	2022
Metabolic profiling integrated with pharmacokinetics to reveal the material basis of Xiaokeyinshui extract combination in the treatment of type 2 diabetes in rats. Journal of pharmaceutical and biomedical analysis, 2023, Feb-20, Volume: 225 Topics: Alkaloids; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drugs, Ch	2023
Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis. Biochemical pharmacology, 2023, Volume: 218 Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Homeostasis	2023
Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 118 Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus,	2019
Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy. European journal of pharmacology, 2020, Apr-15, Volume: 873 Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Berberine; Diabetes Mellitus, Experimental; Diabe	2020
Synthesis of disaccharide modified berberine derivatives and their anti-diabetic investigation in zebrafish using a fluorescence-based technology. Organic & biomolecular chemistry, 2020, 05-13, Volume: 18, Issue:18 Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Disaccharides; Disease Models, Animal;	2020
Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free radical biology & medicine, 2020, 11-01, Volume: 159 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Humans; Lipids; Mice; Mitochondria, Muscle; Muscle, S	2020
Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats. Endocrine, metabolic & immune disorders drug targets, 2021, Volume: 21, Issue:7 Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Berberine; Cell Movement; Cell Proliferation; Ce	2021
Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 131 Topics: Amino Acids, Aromatic; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type	2020
Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: A case report. Journal of integrative medicine, 2021, Volume: 19, Issue:1 Topics: Berberine; Blood Glucose; Child; Diabetes Mellitus, Type 2; Diet; Drugs, Chinese Herbal; Exercise; G	2021
Antidiabetic Effects of Gegen Qinlian Decoction via the Gut Microbiota Are Attributable to Its Key Ingredient Berberine. Genomics, proteomics & bioinformatics, 2020, Volume: 18, Issue:6 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Gastrointestinal Microbiome; H	2020
[Effect of berberine on insulin resistance in diabetic rats]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, 2020, Volume: 36, Issue:6 Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insul	2020
In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications. Journal of ethnopharmacology, 2021, Aug-10, Volume: 276 Topics: Animals; Berberine; Blood Glucose; Body Weight; Computational Biology; Computer Simulation; Diabetes	2021
Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. Frontiers in endocrinology, 2021, Volume: 12 Topics: Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis	2021
Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 94 Topics: Animals; Berberine; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Expe	2017
[Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2016, Volume: 41, Issue:3 Topics: Activating Transcription Factor 2; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Berberine;	2016
Protective role of berberine and Coptischinensis extract on T2MD rats and associated islet Rin‑5f cells. Molecular medicine reports, 2017, Volume: 16, Issue:5 Topics: Animals; Berberine; Blood Glucose; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Cell Survi	2017
Berberine Inhibits Oxygen Consumption Rate Independent of Alteration in Cardiolipin Levels in H9c2 Cells. Lipids, 2017, Volume: 52, Issue:11 Topics: Animals; Berberine; Cardiolipins; Cell Line; Cyclophilins; Diabetes Mellitus, Type 2; DNA Replicatio	2017
Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3β Pathway. Journal of Alzheimer's disease : JAD, 2018, Volume: 65, Issue:4 Topics: Animals; Axons; Berberine; Cells, Cultured; Chromones; Diabetes Mellitus, Type 2; Diabetic Nephropat	2018
SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification. Toxicology letters, 2019, Volume: 301 Topics: Animals; Arsenic; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Electron Transport Complex II	2019
A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats. Clinical and experimental pharmacology & physiology, 2019, Volume: 46, Issue:6 Topics: 3T3 Cells; Adipogenesis; Adipose Tissue, White; Animals; Berberine; Diabetes Mellitus, Type 2; Femal	2019
Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. Scientific reports, 2019, 05-29, Volume: 9, Issue:1 Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Glucokinase; Glucose; Hepatocytes; Hum	2019
Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. The Journal of endocrinology, 2013, Volume: 218, Issue:3 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucagon-Like Peptide 2; Gluco	2013
Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. International journal of pharmaceutics, 2014, Jun-05, Volume: 467, Issue:1-2 Topics: Administration, Oral; Animals; Berberine; Biological Availability; Blood Glucose; Caco-2 Cells; Calo	2014
Synthesis and in vitro evaluation of 12-(substituted aminomethyl) berberrubine derivatives as anti-diabetics. Bioorganic & medicinal chemistry letters, 2014, Apr-01, Volume: 24, Issue:7 Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Diabetes Mellitus, Type 2; Dose-Response Relationship,	2014
Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. BMC complementary and alternative medicine, 2014, Jun-09, Volume: 14 Topics: Animals; Berberine; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experime	2014
Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. Clinical and experimental pharmacology & physiology, 2015, Volume: 42, Issue:6 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammation Mediators; Male;	2015
The marketing of unproven drugs for diabetes and dyslipidaemia in India. The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:10 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych	2015
Indian endocrinologists start debate on diabetes drug. BMJ (Clinical research ed.), 2015, Sep-29, Volume: 351 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych	2015
Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. European journal of pharmacology, 2015, Dec-15, Volume: 769 Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cardiomegaly; Cell Line; Diabetes Mellitus, Type	2015
Effects of berberine and pomegranate seed oil on plasma phospholipid metabolites associated with risks of type 2 diabetes mellitus by U-HPLC/Q-TOF-MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Dec-15, Volume: 1007 Topics: Animals; Berberine; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Lyt	2015
Drug approvals in India. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych	2016
Drug approvals in India. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych	2016
Drug approvals in India - Authors' reply. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych	2016
Berberine Pretreatment Confers Cardioprotection Against Ischemia-Reperfusion Injury in a Rat Model of Type 2 Diabetes. Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:5 Topics: AMP-Activated Protein Kinases; Animals; Arrhythmias, Cardiac; Berberine; Biomarkers; Blood Glucose;	2016
Metabolomics Study of Type 2 Diabetes Mellitus and the AntiDiabetic Effect of Berberine in Zucker Diabetic Fatty Rats Using Uplc-ESI-Hdms. Phytotherapy research : PTR, 2016, Volume: 30, Issue:5 Topics: Animals; Berberine; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drugs, Chinese	2016
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway. PloS one, 2016, Volume: 11, Issue:3 Topics: Acetyl-CoA Carboxylase; Animals; Berberine; Blood Glucose; Carnitine O-Palmitoyltransferase; Cell Su	2016
[Pharmacokinetic and pharmacodynamic characteristics of berberine and jateorhizine in Coptidis Rhizoma powder and their monomeric compounds in type 2 diabetic rats]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2015, Volume: 40, Issue:21 Topics: Animals; Berberine; Blood Glucose; Coptis; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Humans;	2015
Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:1 Topics: Animals; Berberine; Cell Line, Tumor; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female;	2009
Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chinese medical journal, 2008, Nov-05, Volume: 121, Issue:21 Topics: Acrolein; Animals; Berberine; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Glucose Tra	2008
The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Experimental diabetes research, 2008, Volume: 2008 Topics: Alkaloids; Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Disease Model	2008
Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. European journal of pharmacology, 2009, Oct-12, Volume: 620, Issue:1-3 Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary	2009
Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:2 Topics: Adiponectin; Animals; Berberine; Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus,	2011
Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model. Phytotherapy research : PTR, 2011, Volume: 25, Issue:1 Topics: Animals; Anti-Arrhythmia Agents; Berberine; Diabetes Mellitus, Type 2; Disease Models, Animal; Male;	2011
Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocrine journal, 2010, Volume: 57, Issue:10 Topics: Animals; Berberine; Cricetinae; Diabetes Mellitus, Type 2; Female; Gene Expression Profiling; Gene E	2010
Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. European journal of pharmacology, 2010, Dec-15, Volume: 649, Issue:1-3 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiposity; Animals; Berberine; Diabetes Mellitus, Type 2; Do	2010
Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PloS one, 2011, Feb-03, Volume: 6, Issue:2 Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-	2011
Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:5 Topics: Adipose Tissue; Animals; Base Sequence; Berberine; Cricetinae; Diabetes Mellitus, Type 2; DNA Primer	2011
Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice. Planta medica, 2012, Volume: 78, Issue:1 Topics: Acrolein; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Cholesterol, HDL; Ch	2012
Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine. Pharmaceutical biology, 2012, Volume: 50, Issue:8 Topics: Animals; Antioxidants; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Down-Regulation; Glutath	2012
Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012, Dec-15, Volume: 20, Issue:1 Topics: Alkaloids; Animals; Berberine; Blood Glucose; Castanospermum; Diabetes Mellitus, Experimental; Diabe	2012
Berberine improves glucose metabolism through induction of glycolysis. American journal of physiology. Endocrinology and metabolism, 2008, Volume: 294, Issue:1 Topics: 3T3-L1 Cells; Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; AMP-Activated Protein Kin	2008
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae. Yao xue xue bao = Acta pharmaceutica Sinica, 2007, Volume: 42, Issue:12 Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy	2007
[Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research]. Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine, 1988, Volume: 8, Issue:12 Topics: Adult; Aged; Alloxan; Animals; Berberine; Berberine Alkaloids; Blood Glucose; Diabetes Mellitus, Exp	1988

berberine and Diabetes Mellitus, Type 2